Immunophage Biotech announced a comprehensive strategic collaboration with the Shanghai GoBroad Cancer Hospital affiliated to China Pharmaceutical University recently, regarding its independently developed global first-in-class CCR8-targeting small molecule antagonist, IPG7236.
According to the agreement, the hospital will continue to advance the Phase II clinical trials of IPG7236 based on existing clinical trials. IPG7236 is the first CCR8 small molecule antagonist to enter clinical trials globally and is a novel broad-spectrum anti-cancer drug. It is currently transitioning from Phase I to Phase II clinical trials.
Founded in 2016, Immunophage Biotech is an innovative drug development company focused on globally leading targets. The company primarily develops innovative drugs targeting major diseases such as malignant tumors, autoimmune diseases, and neurodegenerative diseases.
Shanghai GoBroad Cancer Hospital, located in the Waigaoqiao Free Trade Zone, has a total building area of 70,000 square meters, with 406 beds available in Phase I. Phase II is under construction and is expected to be operational by 2026.
